Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...
Clinical Trials Arena on MSN
Amgen reports positive Phase III findings for subcutaneous Tepezza trial
The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...
Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...
My niece was diagnosed with birdshot chorioretinopathy.
JENNY Keepe claims ditching her fake lashes helped save her life – as they hid symptoms of a brain tumour caused by her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results